secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-04-11T23:59:59+00:00
Accession:  0000950170-25-053023
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics doses first patient in new 1.5 mCi monotherapy cohort for lead TAT candidate
--------------------------------------------------------------------------------

- First patient dosed in Phase 1/2a trial of [212Pb]VMT01 as monotherapy at 1.5 mCi in MC1R-positive metastatic melanoma.
- Cohort includes patients with brain metastases; prior imaging showed tracer uptake in brain lesions.
- Combination arm with nivolumab began dosing in March 2025; Fast Track Designation from FDA granted September 2024.
- Initial monotherapy results were presented at SMR October 2024; this cohort aims to refine dosing and assess brain metastasis activity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025053023/0000950170-25-053023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025053023/catx-20250411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-053023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer